Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) EBITDA: 2019-2025

Historic EBITDA for Avidity Biosciences (RNA) over the last 7 years, with Sep 2025 value amounting to -$174.5 million.

  • Avidity Biosciences' EBITDA fell 139.49% to -$174.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$555.1 million, marking a year-over-year decrease of 104.46%. This contributed to the annual value of -$319.5 million for FY2024, which is 52.59% down from last year.
  • Latest data reveals that Avidity Biosciences reported EBITDA of -$174.5 million as of Q3 2025, which was down 10.20% from -$158.3 million recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' EBITDA peaked at -$23.8 million during Q1 2021, and registered a low of -$174.5 million during Q3 2025.
  • Over the past 3 years, Avidity Biosciences' median EBITDA value was -$70.8 million (recorded in 2024), while the average stood at -$88.9 million.
  • Data for Avidity Biosciences' EBITDA shows a maximum YoY crashed of 291.82% (in 2021) over the last 5 years.
  • Avidity Biosciences' EBITDA (Quarterly) stood at -$38.7 million in 2021, then dropped by 28.36% to -$49.7 million in 2022, then decreased by 17.57% to -$58.4 million in 2023, then crashed by 82.16% to -$106.5 million in 2024, then crashed by 139.49% to -$174.5 million in 2025.
  • Its EBITDA was -$174.5 million in Q3 2025, compared to -$158.3 million in Q2 2025 and -$115.9 million in Q1 2025.